{"filings":[{"id":1085956,"accession_number":"0001654954-26-006015","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2026-06-16T21:03:40+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"CEL-SCI raises $2.5M in common stock offering for Multikine development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2.5M shares sold at $1.00/share, gross proceeds $2.5M; offering closed June 16, 2026.","Proceeds to fund continued development of Multikine, general corporate purposes, and working capital.","ThinkEquity acted as placement agent; fee of 7% of gross proceeds plus up to $67K expense reimbursement.","Directors and officers subject to 45-day lock-up; company subject to 30-day lock-up on further issuance.","Offered under effective shelf registration (333-288515) with prospectus supplement filed June 14, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":444996,"accession_number":"0001654954-26-004910","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2026-05-14T21:16:25+00:00","items":["1.01","9.01"],"status":"ready","headline":"CEL-SCI enters 50/50 revenue-sharing partnership with Amarox for Multikine in Saudi Arabia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["50%/50% net revenue share for Multikine sales in Saudi Arabia; Amarox exclusive distributor upon SFDA approval.","Amarox ranked #1 for SFDA critical/unavailable medicine applications for 3 consecutive years (2022-2024).","Optional extension to GCC countries (Bahrain, Kuwait, Oman, Qatar, UAE). CEL-SCI retains all IP and global rights.","Partnership targets SFDA Breakthrough Medicine Designation for Multikine in head and neck cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":69603,"accession_number":"0001654954-26-004823","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2026-05-13T20:44:06+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"CEL-SCI raises $7.2M in public offering of 6M shares at $1.20/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $7.2 million from 6,000,000 shares at $1.20 per share.","Net proceeds to fund continued development of Multikine, working capital, and general corporate purposes.","ThinkEquity as sole placement agent; 7.0% cash fee plus up to $150,000 expense reimbursement.","Lock-up: Company 30-day issuance ban; directors/officers 45-day sale ban from May 11, 2026.","Offering closed May 13, 2026; registered under effective S-1 (333-295168)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130450,"accession_number":"0001654954-25-013412","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["3.03","9.01"],"status":"ready","headline":"CEL-SCI board revises Shareholder Rights Agreement on Nov 18, 2025","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Board approved revisions to the Shareholder Rights Agreement effective November 18, 2025.","Revisions modify rights of security holders; full terms are in Exhibit 4 (not provided here).","No specifics on trigger thresholds, dilution, or expiration changes disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130449,"accession_number":"0001654954-25-012607","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["3.03","9.01"],"status":"ready","headline":"CEL-SCI extends shareholder rights plan expiration to October 30, 2030","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board amended the Shareholder Rights Agreement on October 30, 2025.","Rights plan originally adopted November 7, 2007; new expiration date is October 30, 2030.","Full terms described in the Company's S-3 filed August 3, 2018."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147013,"accession_number":"0001654954-25-010184","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"CEL-SCI closes $10M public offering of 1.1M shares at $9.00 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed best-efforts offering of 1,111,200 common shares at $9.00 each; gross proceeds ~$10M.","Placement agent ThinkEquity received 7% cash fee plus up to $185,000 expense reimbursement.","Net proceeds to fund continued development of Multikine and for working capital.","Company agreed to 30-day share issuance standstill; officers/directors subject to 45-day lock-up.","Offering was made under effective Form S-3 shelf registration (File No. 333-288515)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147012,"accession_number":"0001654954-25-009966","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CEL-SCI files Breakthrough Medicine Designation with Saudi FDA for Multikine; signs MOU with Dallah Pharma","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Breakthrough Medicine Designation application filed with SFDA by Dallah Pharma for Multikine.","MOU signed with Dallah Pharma for commercialization; final partnership expected Q3 2025.","SFDA response time ~60 days; if granted, Multikine available for patient access and reimbursement in Saudi Arabia.","Dallah Healthcare serves over 3 million patients annually via network of hospitals and clinics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147011,"accession_number":"0001654954-25-008033","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"CEL-SCI closes $5.7M at-the-market offering of 1.5M shares at $3.82","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$5.73M before placement agent fees (7%) and up to $95K expenses.","Shares sold at $3.82 under NYSE American rules; Offering closed July 14, 2025.","Proceeds to fund continued development of Multikine, general corporate purposes, and working capital.","Directors and officers subject to 45-day lock-up; company has 30-day issuance restriction.","ThinkEquity acted as sole placement agent; offering under existing S-3 shelf registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165521,"accession_number":"0001654954-25-006091","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"CEL-SCI closes $5M public offering of 2M shares at $2.50/share for Multikine development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $5M from 2M shares at $2.50; underwriting discount $0.175 per share.","Underwriters have 45-day over-allotment option for up to 190K additional shares.","Net proceeds to fund continued Multikine development, general corporate, and working capital.","Offering closed May 23, 2025; ThinkEquity acted as sole book-running manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165520,"accession_number":"0001654954-25-005876","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"CEL-SCI shareholders approve stock combination and 2025 equity plans at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Three directors elected: Geert Kersten (21.6M for), Bruno Baillavoine (16.3M for), Robert Watson (16.7M for).","Shareholders approved 2025 Non-Qualified Stock Option Plan and 2025 Stock Bonus Plan.","Stock combination proposal approved with 28.3M votes for, 15.6M against.","BDO USA ratified as independent registered public accounting firm for FY ending Sep 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183161,"accession_number":"0001654954-25-002970","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"CEL-SCI prices $2.56M offering of 16M shares or pre-funded warrants at $0.16/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $2.56M from sale of 4,012,500 shares and pre-funded warrants for 11,987,500 shares.","Offering price $0.16 per share; pre-funded warrants at $0.1599 with $0.0001 exercise price.","ThinkEquity LLC placed the offering; 7% cash fee and up to $80,000 expense reimbursement.","Net proceeds to fund Multikine development, general corporate purposes, and working capital.","Company enters 30-day lock-up on issuance; officers/directors subject to 45-day lock-up."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199735,"accession_number":"0001654954-24-016019","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2024-12-31T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"CEL-SCI closes $5M public offering of 16.1M shares at $0.31 for Multikine development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$5M from 7.55M shares + 8.58M pre-funded warrants at $0.31/$0.3099.","Offering closed Dec 31, 2024; ThinkEquity acted as sole placement agent.","Net proceeds to fund continued development of Multikine, general corporate, working capital.","Directors and officers subject to 45-day lock-up; company has 30-day issuance blackout.","Placement agent fee 7.0% of gross proceeds plus up to $110K expense reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199734,"accession_number":"0001654954-24-014554","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CEL-SCI appoints Patricia Prichep as CFO and COO, effective Nov 13, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patricia B. Prichep, current SVP of Operations, assumes dual CFO and COO role.","Effective date: November 13, 2024.","No mention of prior CFO departure; role expansion from her previous position."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199733,"accession_number":"0001654954-24-014204","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CEL-SCI appoints Dr. Nabil Saba as lead for Phase III Multikine study in head and neck cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Saba will serve as global Phase III confirmatory trial lead and Study Steering Committee member for Multikine.","He is a recognized head and neck cancer expert, professor at Emory, and has led over 50 clinical trials.","Appointment positions CEL-SCI for its upcoming confirmatory registration study in newly diagnosed head and neck cancer.","Dr. Saba chairs NCI head and neck cancer task forces and holds NIH funding for related research."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215754,"accession_number":"0001654954-24-011975","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CEL-SCI reports Multikine 5-year survival 82.6% in target head & neck cancer subgroup; HR 0.27","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Multikine showed 82.6% 5-year overall survival in target low-risk patients vs 47.3% for standard of care.","73% reduction in risk of death (HR 0.27, 95% CI [0.12-0.64], Wald p=0.0027) in that subgroup.","Data presented at ESMO 2024 support confirmatory Registration Study (212 patients) with FDA go-ahead.","Target population: newly diagnosed locally advanced head & neck cancer, no lymph node involvement, low PD-L1.","Phase 3 study subset (n=79) deemed low risk for recurrence per NCCN guidelines, not recommended chemotherapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215753,"accession_number":"0001654954-24-009564","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"CEL-SCI closes $10.8M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $10,845,000 from offering of 10,845,000 shares/common stock or pre-funded warrants at $1.00/share.","Net proceeds to fund continued development of lead cancer drug Multikine and for general corporate purposes.","Offering closed on July 29, 2024; ThinkEquity acted as sole placement agent.","Officers and directors subject to 90-day lock-up on company securities.","Pre-funded warrants exercisable at $0.01 per share and expire when fully exercised."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215752,"accession_number":"0001654954-24-009490","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CEL-SCI bias analysis confirms Multikine survival benefit; 5-year survival 73% vs 45% in target population","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bias analysis found no confounding baseline parameters; treatment and control arms are balanced, no bias detected.","Target population (no lymph node, low PD-L1): Multikine 5-year survival 73% vs 45% control; hazard ratio 0.35.","Company plans 212-patient confirmatory registration study with FDA agreement.","Entire Phase 3 study of 923 patients also showed no bias; CEO notes high confidence in repeating survival benefit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235166,"accession_number":"0001654954-24-007928","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CEL-SCI presents Multikine data: 5yr survival 73% vs 45% control; risk of death halved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Multikine cut risk of death by 50% in low PD-L1 head and neck cancer patients: 73% survival vs 45% control at 5 years.","Hazard ratio 0.35 (95% CI 0.19-0.66, log rank p=0.0015).","Multikine targets low PD-L1 tumor expression, contrasting with checkpoint inhibitors like Keytruda.","Company working to commence FDA confirmatory Registration Study for Multikine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235165,"accession_number":"0001654954-24-004928","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CEL-SCI appoints Mario Gobbo to Board of Directors effective April 19, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mario Gobbo appointed to CEL-SCI Board; will serve on audit, nominating & governance, and compensation committees.","Gobbo has ~40 years of banking/corporate finance experience, currently Managing Partner at Castruccio Advisors LLC.","Previous roles include Lazard (created Central/Eastern European operations), Natixis Bleichroeder, and IFC/World Bank.","Holds BA from Harvard, MS from U. of Colorado, and MBA/PhD from Wharton School."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235164,"accession_number":"0001654954-24-004820","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2024-04-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"CEL-SCI shareholders elect three directors, approve stock option plan and auditor ratification at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Geert Kersten, Bruno Baillavoine, Robert Watson elected as directors with >12M votes each; ~12.8M broker non-votes.","2024 Non-Qualified Stock Option Plan approved: 11.2M for, 2.4M against, 569K abstain.","BDO USA ratified as auditor for fiscal year ending Sep 30, 2024: 26.2M for, 420K against, 303K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252982,"accession_number":"0001654954-24-001679","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"CEL-SCI raises $7.75M in public offering of 3.875M shares at $2.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $7.75M; underwriter discount of $0.14 per share.","Net proceeds to fund Multikine development, general corporate, and working capital.","Offering closed on Feb 13, 2024; ThinkEquity acted as sole book-runner.","Shares offered under effective S-3 shelf registration statement (333-265995)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270459,"accession_number":"0001654954-23-014628","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2023-11-20T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"CEL-SCI raises $4.98M in registered direct offering at $2.00/share; proceeds for Multikine development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 2,490,000 shares at $2.00 per share to a single investor; gross proceeds ~$4.98M.","Underwriters purchased at $1.86/share; ThinkEquity acted as sole book-running manager.","Offering closed on November 20, 2023.","Net proceeds to fund continued development of Multikine, general corporate purposes, and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270458,"accession_number":"0001654954-23-013555","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["1.01","5.02","8.01","9.01"],"status":"ready","headline":"CEL-SCI reports Multikine cuts death risk by half in target head & neck cancer patients; seeks accelerated approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Geert Kersten's employment extended to August 31, 2027.","Multikine shows 28.6% absolute 5-year overall survival benefit vs control (p=0.0015) in target population.","Hazard ratio 0.349; risk of death cut in half at 5 years in target patients.",">35% pre-surgery tumor reductions/downstages (p<0.01) with low PD-L1 expression.","Company plans conditional/accelerated approval worldwide without waiting for new trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270457,"accession_number":"0001654954-23-013323","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2023-10-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CEL-SCI's Multikine shows 28% absolute 5-year survival benefit in head & neck cancer target population at ESMO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Target population: low PD-L1 (<10%), N0, no extracapsular spread; covers ~145,000 patients/year worldwide.","5-year survival 73% with Multikine vs 45% control (p=0.0015); hazard ratio 0.35, 65% risk reduction.","Pre-surgery disease downstaging observed in 35% of Multikine patients; linked to improved survival.","Pre-application regulatory filings submitted in UK and Europe; plans to file in US and Canada for immediate approval without confirmatory study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287413,"accession_number":"0001654954-23-011434","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2023-08-31T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"CEL-SCI extends employment agreements of SVP Prichep and CSO Talor to Aug 2027","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patricia B. Prichep's employment agreement extended to August 31, 2027, terms unchanged.","Eyal Talor, Ph.D.'s employment agreement extended to August 31, 2027, terms unchanged.","Extension effective August 28, 2023; original agreements dated August 31, 2019."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287412,"accession_number":"0001654954-23-009473","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2023-07-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CEL-SCI closes $5M public offering of 2.5M shares at $2.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed underwritten public offering of 2,500,000 common shares at $2.00 per share on July 20, 2023.","Gross proceeds of $5.0M; net proceeds of approximately $4.5M after discounts and expenses.","Proceeds to fund continued development of Multikine and for general corporate purposes.","ThinkEquity acted as sole book-running manager for the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287411,"accession_number":"0001654954-23-009334","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2023-07-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"CEL-SCI prices $5M public offering of 2.5M shares at $2.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $5,000,000 from 2.5M shares at $2.00 per share; net proceeds ~$4.5M.","Offering expected to close July 20, 2023; ThinkEquity sole book-runner.","Net proceeds to fund continued development of Multikine and for general corporate purposes.","Shares offered pursuant to effective shelf registration statement S-3 (File No. 333-265995)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287410,"accession_number":"0001654954-23-009179","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2023-07-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CEL-SCI reports positive FDA meeting for Multikine approval; Canada possible 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA acknowledged need for improved head/neck cancer treatments; CEL-SCI preparing further development plan.","Multikine showed 14.1% absolute OS benefit in lower-risk ITT subjects; 15.2% tumor response in 3 weeks.","Health Canada advised NOCC application; commercialization in Canada could begin as early as 2024.","Upcoming scientific advice meetings with EMA and MHRA in fall 2023.","CEL-SCI plans to file NOCC application in Canada later this year/early next year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287409,"accession_number":"0001654954-23-009042","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2023-07-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cel-SCI reports Multikine Phase 3 biomarker data: 20% 5-year OS benefit in low PD-L1 head & neck cancer patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Low PD-L1 subgroup (TPS<10) showed 20% absolute 5-year overall survival advantage for Multikine+SOC vs SOC alone (60% vs 40% alive).","PD-L1 low subgroup represents >70% of lower-risk patients; hazard ratio 0.68 for LR population all patients.","Data suggest potential to combine Multikine with checkpoint inhibitors like Keytruda or Opdivo for broader coverage.","Company filed patent for Multikine use in tumors with low PD-L1 expression.","Previously reported 14.1% absolute 5-year OS benefit in lower-risk ITT patients; now biomarker confirms effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307559,"accession_number":"0001654954-23-007119","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2023-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"CEL-SCI shareholders elect all directors, approve stock plans and auditor at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected: Geert Kersten, Peter Young, Bruno Baillavoine, Robert Watson, Gail Naughton.","2023 Non-Qualified Stock Option Plan and 2023 Stock Bonus Plan approved by majority of votes cast.","Non-binding advisory vote on executive compensation approved (7,983,457 for, 2,098,246 against).","Frequency of advisory vote set at every 3 years (5,165,164 votes for 3 years vs. 3,740,819 for 1 year).","Ratification of BDO USA as independent auditor for fiscal year ending September 30, 2023 approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307558,"accession_number":"0001654954-23-005645","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CEL-SCI closes public offering of ~913K shares at $1.70, raising ~$1.39M net","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 794,117 shares plus full exercise of 119,117 over-allotment shares at $1.70/share.","Net proceeds of approximately $1,391,900 after underwriting discounts and expenses.","Underwriting agreement with Spartan Capital Securities as representative of underwriters.","Shares sold under effective S-3 shelf registration statement (No. 333-265995).","Over-allotment option exercised in full on closing date of May 2, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307557,"accession_number":"0001654954-23-005494","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"CEL-SCI prices $1.35M common stock offering at $1.70/share; net proceeds ~$1.12M to fund Multikine/LEAPS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 794,117 shares at $1.70 per share; gross proceeds ~$1.35M, net ~$1.12M after discounts and expenses.","Spartan Capital Securities acting as sole book-running manager; 30-day over-allotment option for up to 119,117 additional shares.","Expected to close on or about May 2, 2023; proceeds to fund continued development of Multikine and LEAPS and general corporate purposes.","Offered under effective shelf registration S-3 (No. 333-265995) declared effective July 15, 2022; prospectus supplement filed April 27, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307556,"accession_number":"0001654954-23-004924","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2023-04-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CEL-SCI to pursue Health Canada's conditional approval pathway for Multikine in head & neck cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Health Canada advised CEL-SCI to request approval under Notice of Compliance with Conditions (NOC/c) policy for Multikine.","Plans to file drug submission for earlier access in Canada while preparing U.S. BLA and pursuing other country approvals.","Phase 3 IT-MATTERS study in head & neck cancer showed median OS improvement of 46.5 months for lower-risk patients.","Five-year survival: 62.7% for Multikine vs 48.6% control; tumor shrinkage >30% in ~1 of 6 patients in 3 weeks.","5 patients had complete tumor disappearance in 3 weeks prior to surgery."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326561,"accession_number":"0001654954-23-002577","cik":725363,"company_name":"CEL SCI CORP","ticker":"CVM","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CEL-SCI Multikine Phase 3 shows 43% survival extension; BLA submission planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Multikine extended overall survival by 43% (HR 0.70; 95% CI 0.49-1.00) vs SOC in 352 LR head & neck cancer patients.","5-year survival: 65.3% Multikine arm vs 49.7% control; benefit increased from 2.8% at 3yr to 15.6% at 5yr.","16.5% of Multikine patients had early tumor response (complete pathological) vs 0% control; responders' death rate 15.6% vs 48.7%.","Data presented at ECHNO 2023; company plans to submit BLA to FDA for newly diagnosed locally advanced SCCHN.","Intended patient population ~210,000 annual global cases; no new approved therapy for decades."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21015011.45390071,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}